Schering Sees Return To Earnings Growth And "Turnaround" Phase On Horizon
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering should enter the "turnaround" phase of the company's five-point "action agenda" later in 2005, after two or three quarters of solid performance, CEO Hassan says. Exec cautions progress to date is tenuous: Schering's small product base means a shift in market share for the Zetia/Vytorin franchise could have a big impact on bottom line.
You may also be interested in...
Schering-Plough Sets Acquisition Sights On Specialty Products
The company has entered the third – or “turnaround” – phase of its five-point restructuring program.
Schering-Plough Sets Acquisition Sights On Specialty Products
The company has entered the third – or “turnaround” – phase of its five-point restructuring program.
Merck Tallies Vytorin Switches: 27% From Zocor, 24% From Lipitor
Combined Vytorin and Zetia new prescription share is now 11%, with total prescription share at 10%, Merck reports. Global sales for the drugs were $511 mil. in the first quarter, with $332 mil. from Zetia and $179 mil. from Vytorin.